Eagle Hit With Double Whammy On Vasopressin ANDA Product

ANDA Filer Eagle Has Previously Suggested Launching ‘At Risk’

 
• By Dean Rudge

Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.

Setback
Eagle has quickly seen a trial date shift from January to July, in addition to the CRL. • Source: Shutterstock

More from Generics

More from Products